Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
February 21, 2008

Sirtris Retains NCI to Evaluate Anticancer Agents

  • Sirtris Pharmaceuticals will collaborate with the NCI to test its SIRT1 enzyme activators in different cancer models. The research will include SRT501, a formulation of the antioxidant resveratrol, and multiple compounds from different classes of NCE.

    Sirtris reports that in vitro studies have found these molecules to be 1,000 times more potent than resveratrol. The NCI will test the compounds in well-established cancer cell lines of some of the most common cancer types. The program will also test Sirtris’ compounds using in vivo mouse tumor models to determine if they reduce or limit the growth of the tumor cells.

    “By providing the resources for this study, the National Cancer Institute is accelerating the testing of our compounds in both solid and hematological models of cancer,” remarks Sirtris CEO and vice chair, Christoph Westphal, M.D., Ph.D. “This study will advance our understanding of SIRT1 activation and its potential anticancer properties.”